Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nab-paclitaxel Plus S-1 in Advanced Biliary Tract Adenocarcinoma
NCT03830606Phase 2Completed
- Start
- Mar 2016
- Primary completion
- Sep 2018
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nab-paclitaxel in biliary tract adenocarcinoma. Primary endpoint: Objective Response Rate at 6 months. Started Mar 2016; status: completed.
02
Drugs
nab-paclitaxel
03
Conditions
biliary tract adenocarcinoma
Beyond the preview
Go deeper on NCT03830606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03830606.